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In a prospective multicenter phase II trial of radioembolization with yttrium-90 (90Y-RE) in chemorefractory liver-
dominant metastatic colorectal cancer (mCRC), we showed that median survival was 12.6 months (95% CI 7.0–18.3)
with 48% of 50 patients achieving disease control. In this extension retrospective study, we analyzed whether a
panel of biomarkers, known to be associated to an adverse clinical outcome, underwent variations in CRC liver
metastases pre and post 90Y-RE.
Of the 50 patients included in the study, 29 pre-90Y-RE therapy and 15 post-90Y-RE had liver biopsy specimens
available. In these series we investigated survivin, p53, Bcl-2 and Ki-67 expression pre- and post-90Y-RE by
immuhistochemistry (IHC). Our findings evidenced a decrease of survivin (77% vs 33%), p53 (93% vs 73%), Bcl-2
(37% vs 26%) expression as well as of Ki-67 proliferation index (62.5% vs 40%) on liver biopsies collected post-90Y-RE
as compared to pre-90Y-RE. In the subset of 13 matched liver metastases we further confirmed the reduction of
survivin (92.3% vs 53.8%; p = 0.06), p53 (100% vs 69.2%; p = 0.05) and Bcl-2 (69.2% vs 53.8%; p = 0.05) expression
post-90Y-RE. This biomarker modulation was accompanied by morphological changes as steatohepatitis, hepatocyte
necrosis, collagen deposition, proliferating and/or bile duct ectasia, focal sinusoidal dilatation and fibrosis.
Although our analysis was conducted in a very limited number cases, these changes appear strictly related to the
response to 90Y-RE therapy and may deserve further investigation on a larger series of patients.
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Liver metastases are a significant cause of morbidity and
mortality for more than 45% of patients who present with
colorectal cancer (CRC) [1]. Although chemotherapy regi-
mens combined with biologic agents have improved the
control of liver metastases, the occurrence of hepatic me-
tastases continues to present a life-limiting prognosis for
most patients with advanced CRC [2] being 5 year survival
approximately 11%. In the setting of clinical trials, median
overall survival for unresectable metastases have been ex-
tended beyond two years using combinations including
oxaliplatin, irinotecan, capecitabine and biologic agents
(bevacizumab, cetuximab, panitumumab) [3,4]. In parallel
with these developments, the application of locally ablative
procedures, such as radiofrequency ablation, are increas-
ingly considered beneficial for patients with unresectable
liver-only disease who present with tumors ≤ 3–4 cm in
diameter. These regional treatments for liver metastases
can also be used to consolidate the treatment response with
chemotherapy, in order to further increase the number of
patients eligible for resection [5,6]. Despite these gains, one
of the major challenges in advanced CRC are the growing
proportion of patients who continue to present with pro-
gressive liver involvement having exhausted all other thera-
peutic options.
Radioembolization with yttrium-90 (90Y-RE) and, as re-
cently described, with holmium-166 poly (L-lactic acid) la-
beled microspheres (166Ho-PLLA-MS) [7], are therapeutic
procedures applied to the liver that allow direct delivery of
high-dose radiation to liver tumors (both primary and
metastatic) by means of endovascular catheters, selectively
placed within the hepatic arterial vasculature. 90Y and
166Ho-PLLA-MS (resin or glass) microspheres lodge
within the neovascular rim of the tumor(s) [8,9].
In a multicenter phase II trial conducted in highly
chemorefractory liver-dominant metastatic CRC (mCRC),
we showed that 48% (24 of 50) of patients achieved dis-
ease control with a median overall survival of 12.6
months following RE with 90Y-radiolabelled resin micro-
spheres [10]. This finding is consistent with the results
from other multicenter evaluations using 90Y-RE in the
chemorefractory setting [11]. Up to date, there are no
studies which have investigated biomarker expression
and response to 90Y-RE therapy.
It is largely described that the ability to avoid apoptosis
is one of the major oncogenic switches contributing to
tumor progression. Among the gene coding apoptosis
and cell proliferation protein regulators, Bcl-2, an antia-
popototic protein, survivin, one of the member of the
inhibitor of apoptosis (IAP) protein family and p53 may
identify CRC patients at a higher risk of tumor progres-
sion [12-14].
In the present retrospective study which is an exten-
sion of our previous one [10], we evaluated whether theexpression of these biomarkers may undergo to signifi-
cant changes before and after 90Y-RE thus providing pre-
dictive information of clinical value.
Methods
Patients and treatment
Between May 2005 and August 2007, 50 patients with
unresectable, histologically proven CRC liver metastases
and limited extra-hepatic disease (≤ 3 nodules in the same
extra-hepatic organ each < 3 mm), in progression follow-
ing standard systemic chemotherapy, were recruited from
four Italian centers in a phase II prospective clinical trial
conducted by the Italian Society of Locoregional Therapy
in Oncology (SITILO). Further details of the treatment
planning and patient selection have been outlined in
our previous paper [10]. In brief, patients were required
to be between 18 and 75 years of age, have liver
metastases measurable by Response Evaluation Criteria
in Solid Tumours (RECIST), adequate renal function
(creatinine < 1.5 7 × normal values or creatinine clear-
ance > 50 mL/minute), hemopoietic function, WHO or
ECOG performance status ≤ 2 and were able to give in-
formed consent. To be eligible for 90Y-RE, patients were
required to have: sufficient liver function; hepatic arterial
anatomy that would enable safe delivery of microspheres
to the liver only; liver to lung shunting of < 20% on a pre-
treatment technetium-99m labeled macro-aggregated-al-
bumin (99mTc-MAA) nuclear scan; and a patent main
portal vein. Patients were excluded if they were pregnant,
had evidence of local recurrence of primary disease, in-
flammatory gastrointestinal disease or had received prior
treatment with hepatic arterial chemotherapy or external
beam radiotherapy to the liver. The median interval be-
tween diagnosis of mCRC and 90Y-RE was 17 months
(range, 6–71 months). To investigate biomarkers expres-
sion and response to 90Y-RE therapy, liver metastases
biopsies were taken 8–21 days prior to 90Y-RE and
2 months post-90Y-RE. Tissue specimens were available
from 29 patients pre therapy and 15 patients post ther-
apy. Samples pre- and post-90Y-RE were concomitantly
available in 13 patients.
The study was approved by the Ethical Committee at
the Regina Elena Cancer Institute (N°534; 22/03/05) and
a written informed consent was obtained by all patients.
Immunohistochemistry
Formalin-fixed paraffin-embedded liver biopsies were cut
on SuperFrost Plus slides (Menzel-Gläser, Braunschweig,
Germany). Antigen retrieval was performed at 96°C
(10 mM/L citrate buffer, pH 6) for 40 minutes in a thermo-
static bath. Sections were incubated with the polyclonal
antibody (PAb) anti-survivin (1:100, Novus Biological,
DBA, Milan, Italy); with the anti-Ki-67 monoclonal anti-
body (MoAb) MIB-1 (5 μg/ml; Dako, Milan, Italy), the
Table 1 Expression pattern of survivin, p53 and Bcl-2 in
liver metastases pre- and post -90Y-RE
Biomarkers Number of patients (%)
Pre-90Y-RE (N = 29) Post-90Y-RE (N = 15)
Survivin N (%)
Negative (≤ 20) 5 (16.2) 10 (66.7)
Positive (> 20) 24 (77.4) 5 (33.3)
p53 N (%)
Negative (≤ 10) 2 (6.9) 4 (26.7)
Positive (> 10) 27 (93.1) 11 (73.3)
Bcl-2 N (%)
Negative (≤ 5) 18 (62.1) 11 (73.3)
Positive (> 5) 11 (37.9) 4 (26.7)
Ki-67 N (%)
Negative (<50) 11 (37.5) 9 (60.0)
Positive (≥ 50) 18 (62.5) 6 (40.0)
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MoAb 124 (1,5 μg/ml; Dako) for 30 minutes at room
temperature. Positive and negative controls were in-
cluded for each antibody and in each batch of staining.
Immunoreactions were revealed by a streptavidin-biotin
enhanced immunoperoxidase technique (Super Sensitive
MultiLink Menarini, Florence, Italy) in an automated
autostainer. Diaminobenzidine was used as chromogenic
substrate.
Results were considered positive for survivin when at
least 20% of tumor cells, independent of nuclear or cyto-
plasmic localization, were immunostained, for p53
when 10% of tumor cell nuclei were labelled, for Bcl-2
when > 5% of cells showed a cytoplasmic immunoreaction.
Ki-67 proliferation index, based on the median value of
our series, was regarded as high if greater than 50% of the
cell nuclei were immunostained. Only well preserved
tumor areas were considered for IHC evaluation. The IHC
results were evaluated independently and in a blinded
manner by two investigators (MD, MM).
Statistical analysis
The correlation between biomarkers expression and the
response to 90Y-RE was tested by the Pearson Chi-Square
test and Mac Nemar test. Significance was assessed at 5%
level (p < 0.05). The SPSS statistical software package
version 19.0 was used for analyses (SPSS, Inc, Chicago,
IL, USA).
Results
Expression pattern of survivin, p53, Bcl-2 and Ki-67 in
liver metastases pre- and post-90Y-RE
Of the 50 patients included in the SITILO clinical trial,
29 pre-90Y-RE and 15 post-90Y-RE had sufficient tissue
material from their liver metastases for IHC evaluation
of survivin, p53, Bcl-2 and Ki-67. As reported in Table 1,
we found that, of the 29 liver metastases analyzed pre-
90Y-RE, 24 (77.4%) were survivin positive, 27 (93.1%)
p53 positive,11 (37.9%) Bcl-2 positive and 18 (62.5%)
presented a high Ki-67 proliferation index (>50%). Of
the 15 liver metastases available post-90Y-RE, survivin
was expressed in 5 cases (33.3%), p53 in 11 (73.3%), Bcl-
2 in 4 (26.7%) and Ki-67 was high in 6 lesions (40.0%)
evidencing a variation in biomarker expression pre and
post-90Y-RE.
Changes of survivin, p53, Bcl-2 and Ki-67 in the 13
matched liver metastases pre- and post-90Y-RE
In our series of liver biopsies, 13 patients had matched
valuable tissues pre and post-90Y-RE. As reported in
Table 2, the 13 paired patients, included in biomarker
analysis, were found to be representative of the overall
cohort of the 50 patients enrolled in the SITILO clinical
trial with no statistical differences between the groupsfor baseline parameters (sex, site of primary tumors,
number of metastases, liver involvement, performance
status, bevacizumab or cetuximab therapy). On the basis
of this comparative analysis, we evaluated whether
survivin, p53, Bcl-2 and Ki-67 expression varied pre-
and post-90Y-RE therapy in our series of 13 matched
patients.
As described in Figure 1 panel A, the IHC biomarker
analysis in this subset of mCRC showed that post-90Y-
RE there was a significant reduction in survivin positivity
(from 92% to 54% of samples; p = 0.06) and p53 nuclear
accumulation (from 100% to 69%; p = 0.05) (Figure 1
panel B-a and B-b). Furthermore, we found a small, but
significant, decrease in Bcl-2 positivity (from 46% to
31%; p = 0.05; Figure 1 panel B-c) and a limited, not sig-
nificant, decrease in Ki-67 positivity (from 77% to 61%).
Concerning histological features, we observed that
liver metastases sampled post-90Y-RE presented more
abundant necrosis, with only occasional residual cancer
cells, than those sampled pre-90Y-RE (Figure 2, panel A-
a, A-b). The adjacent liver parenchyma, in both pre- and
post-treatment samples, showed evidence of tissue dam-
age from prior chemotherapy including: steatohepatitis,
hepatocyte necrosis, collagen deposition, proliferating
and/or bile duct ectasia, focal sinusoidal dilatation and
fibrosis (Figure 2, panel A-c).Biomarker variation and response rate pre and post-90Y-
RE in 13 paired liver metastases
In our series of 13 matched patients, 5 presented bio-
marker variations pre and post-90Y-RE therapy and 8 no
biomarker variations. Of clinical interest, 6 of the latter
patients (75%) presented progression disease whereas all
the 5 patients showing changes in biomarker expression
Table 2 Comparison of clinical variables between the overall series of patients and the series with liver biopsies
pre- and post-90Y-RE
Baseline Characteristics
Patients Age (years)* Time to RE** FU months*** Sex N° (%) PT site N° (%) Met N° (%) Liver involvement N° (%) PS N° (%) Pre BV N° (%) Pre CTX N° (%)
M F Colon Rectum ≤ 4 > 4 <25% > 25% 0 ≥ 1 No Yes No Yes
Overall Series (N = 50) 64 19 14 37 13 41 9 21 29 20 7 35 15 39 11 45 5
(34–38) (6–71) (2–49) (74) (26) (82) (18) (42) (58) (40) (54) (70) (30) (78) (22) (90) (10)
Pre/Post RE series (N = 13) 58 21 15 9 4 11 2 4 9 30 6 9 4 9 4 12 1
(40–75) (9–53) (3–49) (69) (31) (85) (15) (31) (69) (60) (46) (69) (31) (69) (31) (92) (8)
P value 0.11 0.50 0.99 0.49 0.99 0.54 0.54 0.99 0.49 0.99
* mean (range); ** Months from diagnosis to 90Y-RE; ***Follow up post-90Y-RE;


















Figure 1 Changes of survivin, p53, Bcl-2 and Ki-67 in liver
metastases pre- and post-90Y-RE. A. The histogram shows the
significant reduction of the positivity of survivin (from 92% to 54%;
p = 0.06), p53 (from 100% to 69%; p = 0.05) and Bcl-2 (from 46% to
31%; p = 0.05) expression in liver metastases pre- and post-90Y-RE
therapy. A limited, not significant decrease in proliferation index by
Ki-67 (from 77% to 61%) is also evident. B. Immunohistochemical
staining of 3 autologous liver metastases sampled pre- and post-
therapy showing a strong decrease in survivin (a) p53 (b), and Bcl-2
(c) immunoreactions.
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Nevertheless, the limited number of patients did not
allow us to determine whether these changes may really
affect survival.
Discussion
Patients included in the present study were from a mul-
ticenter phase II clinical trial which is the first prospect-
ive evaluation of 90Y-RE in CRC patients with liver
metastases who failed previous oxaliplatinum and iri-
notecan based chemotherapy regimen [10]. It has beenwidely reported that alterations in genes, as survivin,
p53 and Bcl-2, which regulate cell growth and apoptotic
processes, are significantly associated to an unfavourable
clinical outcome in CRC patients [15]. In our series of
29 liver mCRC patients, we found that most tumors
sampled prior to 90Y-RE were p53, survivin, and Bcl-2
highly positive and presented a high Ki-67 proliferation
index. In contrast, we found a significant reduction in
p53, survivin and Bcl-2 positive expression in liver me-
tastasis sampled two months post-90Y-RE. There was
also a trend towards a reduction in cells with a high pro-
liferative index as measured by Ki-67. We have previ-
ously shown that colon cancers harboring p53 nuclear
accumulation, as assessed by the DO7 anti-p53 antibody,
represent a subset of tumors with a more aggressive
clinical behaviour in patients with stage II tumors as well
as in young patients [13,16]. Furthermore, several studies
have shown an increased incidence of p53 nuclear accu-
mulation in liver metastases in comparison to the pri-
mary tumor, hypothesizing a role for p53 in CRC liver
metastatization. In particular, the presence of ≥ 3 liver
metastases identified a subset of patients with a very
poor prognosis mainly when associated to p53 mutations
[17]. A number of studies have also shown that tumors
that do not express detectable levels of Bcl-2, but which
exhibited nuclear accumulation of p53, were associated
with the shortest patient survival, while Bcl-2-positive
and p53-negative tumors had the best prognosis [12,17].
Studies conducted at our Institute showed that p53 posi-
tivity combined with Bcl-2 negativity and elevated Ki-67
score correlated with advanced tumor stage, poorly dif-
ferentiated tumors and increased probability of relapse.
Also elevated survivin expression levels in primary CRC
are related to decreased survival [14,15]. In resected liver
tumors, altered expression of survivin, p53, Ki-67 and,
more recently, KRAS mutations, have been shown to be
independently predictive of hepatic recurrence and poor
survival [13,16,18]. It is recently reported that defective
mismatch repair predicts resistance to 5-fluorouracil
(5FU) and KRAS mutation resistance to anti-EGFR anti-
body therapy [19]. Nevertheless, no predictive markers
of RE efficacy in mCRC have been identified up to now.
In terms of the predictive response to radiotherapy, sev-
eral studies have linked epidermal growth factor re-
ceptor (EGFR) and vascular endothelial growth factor
(VEGF) expression to a lack of response to pre-operative
radiotherapy in locally advanced rectal cancer [19-21].
Neither p53, Ki-67 and survivin expression appear to be
correlated to pre-operative chemo-radiotherapy response
and prognosis in locally advanced rectal cancer [22,23]. To
date, however, no study has evaluated the predictive value
of molecular markers on radiosensitivity of CRC liver me-
tastasis. In this context, our findings, although in a very
limited number of patients, may be clinically relevant.
Figure 2 Morphological and phenotypic changes in paired liver metastases pre- and post- 90Y-RE. A. Example of histological features in a
pre-90Y-RE CRC liver metastasis with focal areas of necrosis (a), in a post-90Y-RE CRC liver metastasis with evident increase of tumor necrosis
(b) and, within uninvolved peritumoral liver parenchyma, showing dysplastic hepatocytes, sinusoidal dilatation, leukocyte infiltration and bile-duct
proliferation (c). B. Histogram summarizing Sirtex response in the 13 autologous liver biopsies according to biomarker changes pre- and post-
therapy. Two patients (25%) not showing biomarker changes suffered PD whereas 6 patients (100%) showing biomarker changes had PR or SD.
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series post-90Y-RE may be due to clonal selection or to
epigenetic changes, not previously recorded in this con-
text. Such mechanisms are usually discussed in the con-
text of cell adaption to chemotherapy and evolving
resistance. Radio-sensitivity of colorectal cancer cells may
be determined by p53 mutation [23,24], whereas there is
no evidence that chemotherapy per se cause changes in
the cellular expression of p53 [25]. This is the first time
that we have recorded a down-staging in p53 protein ex-
pression after 90Y-RE.
It is likely that both disease progression and a prolonged
prior chemotherapy affected the efficacy and tolerability of
90Y-RE in the liver. In fact, mild manifestations of non-
alcoholic fatty liver disease (NAFLD) after 5FU [26], more
serious non-alcoholic steatohepatitis after irinotecan and
sinusoidal obstruction syndrome (SOS) after oxaliplatin-
based treatment [27] have been recorded. Using the same
biomarkers as in our study, Panasiuk and colleagues [28]
showed that the intensification of inflammation in NAFLD
may also impact on biomarker expression in human hepa-
tocytes with the induction of pro-apoptotic protein p53
and the inhibition of anti-apoptotic Bcl-2.
There are clear limitations to our study, not least of
which was the small patient numbers and limited tissue
sampling. Nevertheless, we believe that our findings
merit further investigation in prospective clinical trials.
We are planning to evaluate this biomarker panel in a
phase II randomized trial on 2nd line treatment. KRAS
mutated CRC patients with unresectable liver metastasiswill be randomized to receive systemic therapy vs sys-
temic therapy plus 90Y-RE. The combined assessment of
survivin, p53 and Bcl-2 pre and post-90Y-RE therapy
may improve our ability to predict outcomes in the
treatment paradigm of metastatic KRAS mutated CRC
patients.
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